For research use only. Not for therapeutic Use.
Amosulalol (YM 09538) is an orally active and dual inhibitor of α1/β1-Adrenergic Receptor. Amosulalol exhibits antihypertensive activity via α1-Adrenergic Receptor inhibition. Amosulalol decreases reflexogenic increases in heart rate and plasma renin activity (PRA) via β1-Adrenergic Receptor inhibition in spontaneously hypertensive rats (SHR)[1].
Amosulalol (3-30 mg/kg; p.o.; single dose) reduces acute systolic blood pressure in hypertensive rats[1].
Amosulalol (50 mg/kg; p.o.; twice daily for 12 weeks) produces an intolerant antihypertensive effect and also reduces central rate and increases PRA in hypertensive rat models[1].
| Catalog Number | I022108 |
| CAS Number | 85320-68-9 |
| Synonyms | 5-[1-hydroxy-2-[2-(2-methoxyphenoxy)ethylamino]ethyl]-2-methylbenzenesulfonamide |
| Molecular Formula | C18H24N2O5S |
| Purity | ≥95% |
| InChI | InChI=1S/C18H24N2O5S/c1-13-7-8-14(11-18(13)26(19,22)23)15(21)12-20-9-10-25-17-6-4-3-5-16(17)24-2/h3-8,11,15,20-21H,9-10,12H2,1-2H3,(H2,19,22,23) |
| InChIKey | LVEXHFZHOIWIIP-UHFFFAOYSA-N |
| SMILES | CC1=C(C=C(C=C1)C(CNCCOC2=CC=CC=C2OC)O)S(=O)(=O)N |
| Reference | [1]. Honda K, et al. Autonomic and antihypertensive activity of oral amosulalol (YM-09538), a combined alpha- and beta-adrenoceptor blocking agent in conscious rats. Jpn J Pharmacol. 1985 May;38(1):31-41. |
